. Author manuscript; available in PMC: 2014 Jul 31.

Published in final edited form as: Nat Rev Drug Discov. 2014 Feb;13(2):140–156. doi: 10.1038/nrd4204

Table 2.

Selected PI3K Pathway Combination Strategies

Target for combo	Tumor stratification	References
TKs	Active or overexpressed TK	^58,139–144
MEK	Active RTK, RAS mutant	^{26,149,150,155}
BRAF^V600E	Melanoma, colon	^156,157
MYC	MYC amplification, NOTCH mutant	^{27,28,163–165,167}
Autophagy	Glioma, leukemia, others	^168–170
PARP	TNBC	^173,174
Aromatase inhibitors	ER-positive	^104,181
BCL2 antagonists	Leukemia, lymphoma, others	^188–190